Intuitive Surgical reported an 18% increase in procedures year over year as of the end of Q3 2025, driven primarily by adoption of its latest da Vinci 5 surgical system. Hospitals in North America recorded the highest growth, with utilization rates for da Vinci 5 consoles climbing from 55% to 68% over the past twelve months. International markets also contributed meaningfully, with procedure volumes up 15% in Europe and 22% in Asia Pacific. This pure‐play robotics model has allowed Intuitive to concentrate R&D efforts on system enhancements and training programs, reinforcing its position as the category leader in robotic‐assisted surgery.

Recurring revenues now constitute approximately 85% of Intuitive’s total revenue mix, encompassing instrument, accessory and service contracts. This high‐margin annuity stream grew by 20% year over year in Q3, reaching nearly $4.2 billion on an annualized basis. Long‐term service agreements signed with 120 new medical centers during the quarter, each averaging five‐year terms, underpin continued revenue visibility. The replacement cycle for instruments—typically every 10 to 12 procedures—further supports durable consumable demand, insulating the company from fluctuations in capital spending.

Despite robust top‐line momentum, shares trade at a premium relative to peers, reflecting a forward multiple above 40 times consensus earnings estimates. Investors have raised questions about the sustainability of high growth rates as the installed base saturates developed markets. In addition, recent increases in import tariffs on key console components manufactured overseas could add an estimated $50 million to annual production costs starting in early 2026. Management has indicated plans to absorb a portion of these costs through productivity improvements, but any margin pressure could influence near‐term profitability forecasts.